

# 2<sup>nd</sup> European CAR T Cell Meeting

30 January - 1 February 2020  
Sitges, Barcelona (Spain)



EUROPEAN  
HEMATOLOGY  
ASSOCIATION

## Thursday, 30<sup>th</sup> January 2020

12:00 - 12:15	<b>Opening Ceremony</b>	C. Chabannon & H. Einsele (Chairs of the Scientific Programme Committee) N. Kröger & J. Gribben (President EBMT & President EHA)
	<b>Session I: Keynote Lecture</b>	<b>Chairs: C. Chabannon &amp; H. Einsele</b>
12:15 - 12:45	Informed design of engineered T cell therapies for cancer	S. Riddell (United States)
	<b>Session II: Indications for CAR T Cell therapy</b>	<b>Chairs: N. Kröger &amp; J. Gribben</b>
12:45 - 13:15	Acute leukemia	A. Nagler (Israel)
13:15 - 13:45	Myeloma	H. Einsele (Germany)
13:45 - 14:15	Lymphoma	C. Thieblemont (France)
	<b>Session III: Improving the efficacy and safety profile</b>	<b>Chairs: M. Hudecek &amp; C. MacKall</b>
14:15 - 14:35	Targeted genomic insertion	D. Büsch (Germany)
14:35 - 14:55	Virus-free gene transfer & genome editing	Z. Ivics (Germany)
14:55 - 15:15	Adapter/Uni-CARs	G. Ehninger (Germany)
15:15 - 15:45	<b>Coffee break</b>	
	<b>Session IV: Keynote lecture</b>	<b>Chairs: A. Baruchel &amp; M. Heemskerk</b>
15:45 - 16:15	Engineering Next Generation CAR T cells to Overcome Resistance	C. MacKall (United States)
	<b>Session V: CAR T in pediatrics</b>	<b>Chairs: A. Baruchel &amp; M. Heemskerk</b>
16:15 - 16:35	Post transplant relapse-Second SCT or CAR T-cells	P. Bader (Germany)
16:35 - 16:55	Neuroblastoma	F. Locatelli (Italy)
16:55 - 17:15	Bispecific CAR T Cells	P. Amrolia (United Kingdom)
	<b>Session VI: Keynote Lecture</b>	<b>Chairs: C. Chabannon &amp; H. Einsele</b>
17:15 - 17:45	Improved CAR T cell approaches for lymphoid malignancies	M. Pule (United Kingdom)
	<b>Session VII: Best Abstracts &amp; Flash Talks - Part 1</b>	<b>Chairs: C. Chabannon &amp; H. Einsele</b>
17:45 - 18:45	Oral presentations: D. Madduri (US) RM. Monjezi (Germany) E. Donnadieu (France)	Flash Talks: M. Keränen (Finland)      B. de Angelis (Italy) S. Tettamanti (Italy)      B. Greco (Italy) CF. Magnani (Italy)      M. Topp (Germany)
18:45 - 19:30	<b>Satellite Symposium sponsored by Celgene</b> <b>Recent Advances in CAR T cell therapy for haematological malignancies   Chair: J. Abramson</b> J. Abramson (United States) & MV. Mateos (Spain)	
19:30 - 20:30	<b>Welcome reception &amp; poster session</b>	

## Friday, 31<sup>st</sup> January 2020

	<b>Session VII: Latest clinical &amp; pre-clinical data. Part 1</b>	<b>Chairs: J. Kuball &amp; B. Levine</b>
8:30 - 8:50	ROR1 CAR T cell therapy in CLL and solid tumors	J. Specht ( <i>United States</i> )
8:50 - 9:10	Novel CAR targets for multiple myeloma	N. Hosen ( <i>Japan</i> )
9:10 - 9:30	Liso-cel pivotal TRANSCEND data	J. Abramson ( <i>United States</i> )
	<b>Session IX: Keynote Lecture</b>	<b>Chairs: J. Kuball &amp; B. Levine</b>
9:30 - 10:00	Updates in CAR T cell therapy	C. June ( <i>United States</i> )
	<b>Session X: Latest clinical &amp; pre-clinical data. Part 2</b>	<b>Chairs: J. Kuball &amp; B. Levine</b>
10:00 - 10:20	CD30 memory T cells for Hodgkin and T cell lymphoma	J. Briones ( <i>Spain</i> )
10:20 - 10:40	L1CAM-specific CAR T cell therapy for childhood neuroblastoma	A. Künkele ( <i>Germany</i> )
10:40 - 11:00	iPS CARs	M. Themeli ( <i>Netherlands</i> )
11:00 - 11:30	<b>Coffee break</b>	
	<b>Session XI: Best Abstracts &amp; Flash Talks - Part 2</b>	<b>Chairs: M. Hudecek &amp; A. Urbano-Ispizua</b>
11:30 - 12:30	Oral Presentations: M. Seif ( <i>Germany</i> ) M. Doglio ( <i>Italy</i> ) S. Lykopoulos ( <i>United Kingdom</i> )	Flash talks: A. Alonso-Saldrigues ( <i>Spain</i> )    C. Berger ( <i>Germany</i> ) A. Fernandez ( <i>Spain</i> )                W. Hazelton ( <i>UK</i> ) J. Liu ( <i>China</i> )                            A. Harden ( <i>USA</i> )
	<b>Session XII: Keynote Lecture</b>	<b>Chairs: M. Hudecek &amp; A. Urbano-Ispizua</b>
12:30 - 13:00	Current CAR T Trial activities in China	JX. Wang ( <i>China</i> )
13:00 - 13:45	<b>Lunch break</b>	
13:45 - 14:30	<b>Satellite Symposium sponsored by Kite (a Gilead Company)</b> <b>Redefining survival in DLBCL: The role of CAR T   Chair: A. Sureda</b> A. Sureda, R. Sanderson & N. Bolaños	
	<b>Session XIII: Keynote Lecture</b>	<b>Chairs: I. Yakoub-Agha &amp; D. Büsch</b>
14:30 - 15:00	The emergence of synthetic immunity	M. Sadelain ( <i>United States</i> )
	<b>Session XIV: CAR Effector Cells</b>	<b>Chairs: I. Yakoub-Agha &amp; D. Büsch</b>
15:00 - 15:20	CAR expressing NK cells for cancer retargeting	K. Rezvani ( <i>United States</i> )
15:20 - 15:40	Allogeneic CAR T cells	W. Qasim ( <i>United Kingdom</i> )
15:40 - 16:00	CAR-NK cells as off-the-shelf therapeutics bridging innate and adaptive immunity	W. Wels ( <i>Germany</i> )
	<b>Session XV: Optimizing CAR T treatment</b>	<b>Chairs: M. Mohty &amp; P. Pedrazzoli</b>
16:00 - 16:20	Microbiome	M. van den Brink ( <i>United States</i> )
16:20 - 16:40	Visualizing CAR T-cells at work	J. Huppa ( <i>Austria</i> )
16:40 - 17:00	Improving CART-cells in solid tumors	S. Guedan ( <i>Spain</i> )
17:00 - 17:30	<b>Coffee break &amp; Industry theater session by BD Biosciences</b>	
	<b>Session XVI: CAR T regulatory session</b>	<b>Chairs: N. Bolaños &amp; W. Herr</b>
17:30 - 17:52	Marketing authorization of CAR T cells - the EMA perspective	M. Schüssler-Lenz ( <i>Germany</i> )
17:52 - 18:14	Creating a country-wide selection algorithm (The Austrian experience)	U. Jäger ( <i>Austria</i> )
18:14 - 18:38	PASS and PAES: The need for registration, short- and long-term follow-up of patients treated with gene therapy medicinal products	C. Chabannon ( <i>France</i> )
18:38 - 19:00	Patients' perspective	B. Verhoeven ( <i>Netherlands</i> )
19:00 - 19:45	<b>Satellite Symposium sponsored by Novartis</b> <b>CART from the trial design to RWE in DLBCL   Chair: C. Solano</b> F. Ciceri ( <i>Italy</i> ) & I. Avivi ( <i>Israel</i> )	

# 2<sup>nd</sup> European CAR T Cell Meeting

30 January - 1 February 2020  
Sitges, Barcelona (Spain)



## Saturday, 1<sup>st</sup> February 2020

GENERAL SESSION			NURSES SESSION			DATA MANAGERS SESSION		
	Session XVII: European Grants/Projects	Chairs: C. Bonini & C. Chomienne		Session XVIII: Patient care 1	Chairs: J. Murray & E. Aerts		Session XIX: D M Session 1	Chair: A. van Biezen
8:30 - 8:48	CARAMBA (H2020, SLAMF7 CAR-T)	M. Hudecek (Germany)	8:30 - 8:35	Introduction and Welcome	J. Murray (UK) & E. Aerts (Switzerland)	8:30 - 8:55	Content of the Advanced Cellular Therapies form	C. Chabannon (France)
8:48 - 9:06	EURECAT (H2020, CD44v6 CAR-T)	F. Ciceri (Italy)	8:35 - 9:05	The science of IEC and what is new	E. Vickers (United Kingdom)	8:55 - 9:20	The Advanced Cellular Therapies form in MACRO   Data entry overview	L. Stolarczyk (United Kingdom)
9:06 - 9:24	CARAT (H2020; CAR-T manufacturing)	M. Assenmacher (Germany)	9:05 - 9:25	Solid Tumours and IEC	T. Garcia Lopez (United Kingdom)	9:20 - 9:45	CAR T data collection   CIBMTR experience	M. Pasquini (United States)
9:24 - 9:45	imSAVAR	U. Köhl (Germany)	9:25 - 9:45	Clinical Trial updates	I. Yakoub-Agha (France)			
9:45 - 10:15	<b>Coffee break &amp; Industry theater session sponsored by Kite (a Gilead Company)</b>							
	Session XX: Management of side effects (Round table discussion)	Chairs: A. Mackensen & To be announced		Session XXI: Patient care 2	Chairs: J. Murray & E. Aerts		Session XXII: D M Session 2	Chair: M. Pasquini
10:15 - 10:35	B-cell aplasia and hypogammaglobulinemi / Neurotoxicity and management of CRS	A. Baruchel (France)	10:15 - 10:35	Apheresis in Adults and Paediatrics	D. Hutt (Israel)	10:15 - 10:40	Follow-up of CAR T Cell treatments - The EMA Registry Initiative	J. Kuball (Netherlands)
10:35 - 10:55	Cytopenia	To be announced	10:35 - 10:55	Real world experience of commercial IEC	A. Abia Hereu (Spain)	10:40 - 11:05	Follow-up of gene therapies used to treat inborn errors	To be announced
10:55 - 11:15	Disease and age groups	M. J. Kersten (Netherlands)	10:55 - 11:15	Managing expectations	M. Kenyon (United Kingdom)	11:05 - 11:30	PASS studies	A. van Biezen (Netherlands)
11:15 - 11:35	Guidelines	I. Yakoub-Agha (France)	11:15 - 11:35	Psychology and CAR-T	P. Alexander (United Kingdom)	11:30 - 11:55	Toxicities in CAR T therapy   Recognition and management	R. Benjamin (United Kingdom)
11:35 - 12:00	Discussion		11:35 - 12:00	CAR-T ineligible what now?	M. Pamiás Nogué	11:55 - 12:00	Q&A	
12:00 - 13:00	<b>Lunch Break</b>							
GENERAL SESSION			NURSES SESSION			PHYSICIANS SESSION		
	Session XXIII: Implementation of CAR-T Cells in the real world	Chairs: C. Rössig & A. Nagler		Session XXV: Patient care III	Chair: J. Murray & E. Aerts		Session XXIV: Manufacturing of CAR T Cell in an Academic setting	Chairs: U. Köhl & A. Urbano-Ispizua
13:00 - 14:20	Round table discussion	S. Mielke (Sweden)	13:00 - 13:25	Nursing guidelines and Network for IEC	R. Ellard (United Kingdom)	13:00 - 13:15	London Group	C. Roddie (United Kingdom)
13:20 - 13:40		G. Salles (France)	13:25 - 13:50	Nurse training program	R. Clout (United Kingdom)	13:15 - 13:30	Tel Aviv Group	E. Jacoby (Israel)
13:40 - 14:00		M. Mahty (France)	13:50 - 14:10	The patient experience	LA. Latorre (Spain)	13:30 - 13:45	Barcelona Group	M. Juan (Spain)
14:00 - 14:20		M. Pasquini (United States)	14:10 - 14:30	Relapse post CAR-T options	M. Berquier (France)	13:45 - 14:00	Frankfurt Group	H. Böning (Germany)
14:20 - 14:30	Q&A					14:00 - 14:30	Q&A	
14:30 - 15:00	<b>Coffee break</b>							
	Session XXVI: Manufacturing of CAR T cell in an Industrial setting	Chairs: N. Kröger & J. Gribben		Session XXVII: Patient care IV	Chair: J. Murray		Session XXVIII: CAR-T Health Technology Assessment: What is the value of CAR-T?	Chairs: M. Hudecek & V. Jacquemin
15:00 - 15:20	Academia - industry partnering to develop innovative CAR-T Cells	B. Levine (United States)	15:00 - 15:45	Panel Discussion & Meet the experts:  M. Ni Chonghaile (Ireland) E. Aerts (Switzerland) JM. Cano Ruiz (Spain) D. Hutt (Israel) R. Ellard (United Kingdom)		15:00 - 15:22	Reimbursement in Germany, DRG and CAR-T	C. Haag (Germany)
15:20 - 15:40	Point-of-care manufacturing (POC) as an alternative to central manufacturing	G. Rauser (Germany)				15:22 - 15:44	Industry perspective: price and value of CAR T, pros and cons of different reimbursement models and overall socioeconomic impact	E. Ostuni (Switzerland)
15:40 - 16:00	Expanding CAR T into the commercial setting: planning for success	B. Dudek				15:44 - 16:04	HTAs for approved and pipeline CAR T products, reimbursement models and overall socioeconomic impact	J. Sindern (Belgium)
16:00 - 16:20	Building a Swiss timepiece: The evolution of global CAR T industrial manufacturing	D. Ledergerber				16:04 - 16:26		C. Uyl-de Groot (Netherlands)
16:20 - 16:30	Q&A							
16:30 - 16:45	Closing Remarks	C. Chabannon & H. Einsele						

# Poster Index

---

## Acute lymphoblastic leukemia Biology & Translational Research

### P01 A NOVEL BIESPECIFIC CD19 AND CD22-DIRECTED CAR FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

S.R. Zanetti (Josep Carreras Leukaemia Research Institute, Barcelona, Spain)

## Acute lymphoblastic leukemia Clinical

### P02 SAFETY AND EFFICACY OF CD19 CAR T-CELLS AGAINST CNS LEUKEMIA

E. Jacoby (Sheba Medical Center, Tel Hashomer, Israel)

### P03 EXPERIENCE IN CAR-T CELL THERAPY IN A PEDIATRIC INTENSIVE CARE UNIT

S. Bobillo (Hospital Sant Joan de Déu, Barcelona, Spain)

### P04 IMMUNOLOGICAL CHANGES AFTER ANTI-CD19 CAR T-CELL THERAPY IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.

A. Deya-Martinez (Hospital Sant Joan de Deu, Esplugues de Llobregat, Spain)

### P05 UTILIZATION OF CAR-T CELL THERAPY IN PEDIATRIC PATIENTS, NURSING OVERVIEW AT SANT JOAN DE DÉU BARCELONA CHILDREN'S HOSPITAL

C. Llanos (Sant Joan de Déu Foundation, Sant Joan de Déu Research Institute, Esplugues de Llobregat, Spain)

### P06 ACADEMIC, PHASE I/II TRIAL ON T CELLS EXPRESSING CD19 CHIMERIC ANTIGEN RECEPTORS AND INDUCIBLE CASPASE 9 SAFETY SWITCH FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA AND NON-HODGKIN LYMPHOMA IN CHILDREN

F. del Bufalo (IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy)

### P07 APHERESIS LYMPHOCYTE COLLECTION FOR CAR T CELL PRODUCTION IN PEDIATRIC AND YOUNG ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: THE SANT JOAN DE DÉU BARCELONA CHILDREN'S HOSPITAL EXPERIENCE.

S. Rives (CAR-T Cell Unit, Hospital Sant Joan de Déu, Esplugues Llobregat, Barcelona, Spain)

### P08 POST CAR T-CELL THERAPY PROGRESSIVE SUBRETINAL LEUKEMIC RELAPSE: A CASE REPORT.

B. Allahyani (Children's Hospital of Eastern Ontario, Ottawa, Canada)

### P09 CAR-T CELLS FOR RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN THE EYE: A CASE REPORT

B.J. Vormoor-Burger (Prinses Maxima Center for Pediatric Oncology, Utrecht, The Netherlands)

# Poster Index

---

### P10 POINT-OF-CARE PRODUCTION OF CD19 CAR-T CELLS IN AN AUTOMATED CLOSED-SYSTEM: ROBUST MANUFACTURING AND HIGH CLINICAL EFFICIENCY

O. Molostova (Dmitriy Rogachev National Medical Research Centre of Pediatric Hematology, Moscow, Russia)

## Acute myeloid leukemia Biology & Translational Research

### P11 4-1BB-BASED CD123-REDIRECTED T-CELLS ABLATE HUMAN NORMAL HEMATOPOIESIS IN VIVO

M. Libero Baroni (Josep Carreras Leukemia Research Institute, Barcelona, Spain)

### P12 OPTIMIZED CART CELLS TARGETING CD33 FOR IMPROVED THERAPIES AGAINST R/R AML

J.R. Rodriguez-Madoz (Hemato-Oncology Programme, CIMA Universidad de Navarra. IdiSNA., Pamplona, Spain)

### P13 NKG2D CHIMERIC ANTIGEN RECEPTOR-EXPRESSING LYMPHOCYTES TARGET ACUTE MYELOID LEUKEMIA CELLS

A.L. Leivas (Hospital Universitario 12 de Octubre, H12O-CNIO Haematological Malignancies Clinical, Madrid, Spain)

## Chronic lymphocytic leukemia and related disorders Biology & Translational Research

### P14 IMPACT OF GENETICS ON THE PERFORMANCE OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

V. Mancikova (Central European Institute of Technology (CEITEC), Brno, Czech Republic)

## Myeloma and other monoclonal gammopathies Biology & Translational Research

### P15 PREFERENTIAL EXPANSION OF CD8+ T CELL CENTRAL MEMORY CELL SUBSET OF JNJ-4528 BCMA-TARGETED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY: TRANSLATIONAL ANALYSIS FROM CARTITUDE-1, AN ONGOING PHASE 1B/2 STUDY IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOM

E. Zudaire (Janssen R&D, Spring House, United States)

### P16 T-CELL-EXPANSION AND TRANSDUCTION 3 MONTHS AFTER HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

T. Mika (Knappschaftskrankenhaus Bochum, Bochum, Germany)

### P17 EARLY MEMORY CAR T CELLS WITH SUPERIOR EXPANSION CAPACITY USING TEMPORARY AKT INHIBITION

A.B. van der Waart (Radboud Institute of Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands)

# Poster Index

---

## **P18 IMPACT OF RETRONECTIN@-MEDIATED T-CELL ACTIVATION ON EXPANSION AND PHENOTYPE OF CAR-T CELLS**

R. Uchibori (Jichi Medical University, Shimotsuke, Japan)

## **Non-Hodgkin lymphoma Clinical**

## **P19 ASSESSING CLINICAL PARAMETERS PREDICTING CYTOKINE RELEASE SYNDROME (CRS) IN DLBCL PATIENTS UNDERGOING CAR-T THERAPY.**

T. Pabst (University Hospital, Bern, Switzerland)

## **P20 MSKCC EARLY EXPERIENCE USING RADIOTHERAPY AS A BRIDGING STRATEGY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA BEFORE CD19 CAR T THERAPY**

B.S. Imber (Memorial Sloan Kettering Cancer Center, New York City, United States)

## **P21 INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL)**

O.O. Oluwole (Vanderbilt-Ingram Cancer Center, Nashville, United States)

## **P22 OUTCOME AND CAUSES OF NON-ELIGIBILITY FOR CD19 CAR-T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA.**

C. Carpio (Hospital Universitari Vall d'Hebron, Barcelona, Spain)

## **P23 INFLUENCE OF CD27- CD28- T-CELLS ON THE THERAPEUTIC OUTCOME IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AFTER CART-INFUSION**

N.W. Worel (Medical University Vienna, Vienna, Austria)

## **P24 KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): RESULTS OF THE PHASE 2 ZUMA-2 STUDY**

M.J. Kersten (Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands)

## **P25 A COMPARISON OF 2-YEAR OUTCOMES IN ZUMA-1 (AXICABTAGENE CILOLEUCEL) AND SCHOLAR-1 IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA**

S.S. Neelapu (The University of Texas MD Anderson Cancer Center, Houston, United States)

## **P26 AN OBSERVATIONAL PROSPECTIVE STUDY ON THE REAL LIFE ACCESSIBILITY TO CAR T CELLS: FROM CLINICAL FEASIBILITY TO MOLECULAR MONITORING OF DISEASE RESPONSE IN DIFFUSE LARGE B—CELL LYMPHOMAS**

A. Guidetti (University of Milan & Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

# Poster Index

---

## **P27 THE IN-HOUSE MANUFACTURING PROCESS OF CD19 CAR-T FOR R/R NON-HODGKIN LYMPHOMA - EXPERIENCE OF A SINGLE CENTER**

K. Ohmine (Jichi Medical University, Shimotsuke-shi, Japan)

## **P28 HYDROCORTISONE DURING CAR T INFUSION DOES NOT REDUCE CAR T CELL FUNCTION IN PATIENTS WITH ADRENAL INSUFFICIENCY**

C.R. Schultze-Florey (Hannover Medical School, Hannover, Germany)

## **P29 REAL-WORLD RESULTS OF AN ANTI-CD19 CAR T-CELL AXICABTAGENE CILOLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA INCLUDED IN A FRENCH EARLY ACCESS PROGRAMME**

C. Thieblemont (Hémato-oncologie, Assistance Publique Hôpitaux de Paris - Hôpital Saint-Louis, Paris, France)

## **P30 HEMATOTOXICITY AND INFECTIOUS COMPLICATIONS OF CD19-CAR T CELL TREATED PATIENTS: REAL LIFE DATA FROM MUNICH (LMU)**

K.R. Rejeski (LMU Munich, Munich, Germany)

## **P31 THE USE OF LIQUID BIOPSY FOR DISEASE MONITORING AFTER ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL IN DIFFUSE LARGE B-CELL LYMPHOMA**

C. Maluquer Artigal (Institut Catala Oncologia - Hospital Duran I Reynals. Fundació Idibell, Hospitalet De Llobregat, Spain)

## **P32 TREATMENT WITH CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AFTER A PRECEDING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IS FEASIBLE AND SAFE IN PATIENTS WITH B-CELL LYMPHOMA.**

M.L. Schubert (University Hospital Heidelberg, Heidelberg, Germany)

## **P33 REAL-WORLD EVIDENCE OF THE USE OF TISAGENLECLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS. THE SPANISH EXPERIENCE.**

G. Iacoboni (Vall D'Hebron University Hospital, Barcelona, Spain)

## **P34 EARLY EXPERIENCE USING RADIOTHERAPY AS A SALVAGE TREATMENT FOR RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS FOLLOWING CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY**

B.S. Imber (Memorial Sloan Kettering Cancer Center, New York City, United States)

## **P35 CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - THE MUNICH REAL LIFE EXPERIENCE**

V. Bücklein (University Hospital, LMU Munich, Munich, Germany)

# Poster Index

---

## Gene therapy, cellular immunotherapy and vaccination Biology & Translational Research

### **P36 NOVEL HUMANIZED ANTIBODIES AND CAR-T AGAINST PRAME-POSITIVE TUMORS**

A.V. Misyurin (GeneTechnology LLC, Moscow, Russia)

### **P37 CD19 REDIRECTED CAR NK CELLS ARE EQUALLY EFFECTIVE BUT LESS TOXIC THAN CAR T CELLS**

C. Quintarelli (Bambino Gesù Children's Hospital, IRCCS, Rome, Italy)

### **P38 MEMORY STEM T CELLS (TSCM) TRANSDUCED WITH A CAR30 TARGETING A MEMBRANE-PROXIMAL CD30 EPITOPE CONFERS SUPERIOR T-CELL LYMPHOMA REACTIVITY IN VITRO AND A POTENT ANTITUMOR EFFECT IN VIVO**

L. Escribà-Garcia (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

### **P39 SET UP OF A MANUFACTURING PLATFORM FOR DELIVERY OF MODIFIED T-CELLS FOR THERAPEUTIC APPLICATION: THE UCL TRANSLATION TEAM EXPERIENCE**

A. Cadinanos-Garai (University College London, London, United Kingdom)

### **P40 COMPARISON OF MANUAL AND AUTOMATED CD19 CAR-T CELLS MANUFACTURING METHODOLOGIES**

J. Dias (University College London, London, United Kingdom)

### **P41 HIGH CAR EXPRESSION CONFERS ENHANCED ANTITUMOR EFFECT AGAINST B-CELL AND HODGKIN'S LYMPHOMA.**

A. Caballero (Hospital de la Santa Creu i Sant Pau/Josep Carreras Leukaemia Research Institute, Barcelona, Spain)

### **P42 PRECLINICAL ASSESSMENT OF EFFICACY AND SAFETY ANALYSIS OF THE CAR-T CELLS TARGETING CD19-EXPRESSING B CELLS FOR THE FIRST TURKISH ACADEMIC CLINICAL TRIAL WITH ALL AND NHL PATIENTS**

Kançagi (Acibadem Labcell Laboratory, Istanbul, Turkey)

### **P43 GAMMA-DELTA CAR T-CELLS SHOW CAR-DIRECTED AND INDIRECT ACTIVITY AGAINST LEUKEMIA**

R.M. Rozenbaum (Tel Hashomer - Sheba medical center, Ramat Gan, Israel)

### **P44 GUT MICROBIOTA SIGNATURES AS PREDICTIVE BIOMARKERS FOR RESPONSE AND TOXICITIES IN BCP-ALL AND DLBCL PATIENTS AFTER TREATMENT WITH CD19 SPECIFIC CAR T CELLS**

V. Blumenberg (University Hospital, LMU, Munich, Germany)

# Poster Index

---

### **P45 IDENTIFICATION OF A TUMOR-SPECIFIC ALLO-HLA-RESTRICTED ??TCR**

I. Johanna (University Medical Center Utrecht, Utrecht, The Netherlands)

## Gene therapy, cellular immunotherapy and vaccination Clinical

### **P47 TEG001 INSERT INTEGRITY FROM VECTOR PRODUCER CELLS UNTIL MEDICINAL PRODUCT**

T. Straetemans (University Medical Center Utrecht, Utrecht, The Netherlands)

### **P48 CHARACTERISTICS OF ICU ADMISSIONS OF ADULT PATIENTS WITH B-CELL MALIGNANCIES TREATED WITH ARI-0001 CELLS (AN ACADEMIC CART-19)**

P.C. Castro (Hospital Clínic de Barcelona, Barcelona, Spain)

### **P49 ADVERSE OUTCOME OF PATIENTS WITH LEG TYPE AND TRIPLE HIT LYMPHOMA AFTER CD19 CAR-T-CELL THERAPY, A SINGLE CENTER EXPERIENCE**

V.P. Victoria Panagiota (Hannover Medical School, Hannover, Germany)

### **P50 RISK MANAGEMENT ASSESSMENT IN IMPLEMENTING CAR-T CELL THERAPY IN A CLINICAL UNIT**

A.M. Berthelsen (Rigshospitalet, Copenhagen, Denmark)

### **P51 FLOWCHART FOR SYSTEMATIC DETECTION AND SYMPTOM MANAGEMENT OF CYTOKINE RELEASE SYNDROME POST CAR-T CELL TREATMENT**

C. Borch Jacobsen (University Hospital of Copenhagen, Copenhagen, Denmark)

### **P52 GMP-COMPLIANT MANUFACTURING OF NKG2D CAR MEMORY T CELLS USING CLINIMACS PRODIGY**

F. Fernández (CNIO, Madrid, Spain)

### **P53 LANGUAGE DYSFUNCTION ASSOCIATED EEG FINDINGS IN PATIENTS WITH CAR-T RELATED NEUROTOXICITY.**

E. Sokolov (Massachusetts General Hospital, Boston, United States)

### **P54 CART19-BE-01: A EUROPEAN ACADEMIC TRIAL ON THE ADMINISTRATION OF ARI-0001 CELLS IN PATIENTS WITH CD19+ LYMPHOPROLIFERATIVE DISORDERS**

V. Ortiz-Maldonado (Hospital Clínic, Barcelona, Spain)

### **P55 DEVELOPMENT OF A KNOWLEDGE TEST ON IMMUNO-T, A MOTION COMIC EXPLAINING HOW 3 FORMS OF IMMUNOTHERAPY WORK.**

T. Kerre (Ghent University Hospital, Ghent University, CanSoRG, Gent, Belgium)

# Poster Index

---

## Clinical implementation of immune effector cell based therapies, including combinatorial approaches with other immune therapies

### **P56 THE HEIDELBERG TRIAL 1 (HD-CAR-1 TRIAL): TREATMENT WITH CD-19-DIRECTED THIRD-GENERATION CAR T CELLS DISPLAYS AN EXCELLENT SAFETY PROFILE AND MIGHT IMPROVE PERSISTENCE OF CAR T CELLS**

M.L. Schubert (University Hospital Heidelberg, Heidelberg, Germany)

### **P57 ALLOGENEIC HSCT AFTER CAR T CELLS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA. BRIDGING ONLY AFTER CAR-T CELL LOSS?**

E. González Forster (Hospital Sant Joan de Déu, Barcelona, Spain)

### **P58 CLINICAL IMPLEMENTATION AND EDUCATION: GETTING THE WIDER WORKFORCE READY FOR IMMUNE EFFECTOR CELLS**

L. McNab (The Christie NHS Foundation Trust, Manchester, United Kingdom)

### **P59 NEUROLOGICAL MANAGEMENT AND WORK-UP OF 10 ADULT CAR T CELL PATIENTS WITH RELAPSED OR REFRACTORY B-CELL LYMPHOMA**

N. Möhn (Hannover Medical School, Hannover, Germany)

### **P60 ANALYSIS OF CONTINUOUS REMISSION DUE TO CAR-T THERAPY IN A CASE OF DOUBLE EXPRESSION DIFFUSE LARGE B-CELL LYMPHOMA RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION**

Y. Zang (Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital, Zhengzhou, China)

## Solid tumor and autoimmune disorders

### **P61 "CAR T CELL TREATMENT FOR SOLID TUMOURS: YET NOT THERE"**

M.A. Salvino (HSR Oncologia D'or- UFBA, Salvador, Brazil)

### **P62 ERBB2-CHIMERIC ANTIGEN RECEPTOR (CAR)-ENGINEERED NATURAL KILLER NK92-CELL LINE (NK92/S.28.Z) FOR CLINICAL USE IN HIGH-RISK SOFT TISSUE SARCOMAS IN CHILDREN AND YOUNG ADULTS**

M. Merker (University Hospital, Goethe University, Frankfurt/Main, Germany)

# Poster Index

---

## Medico-economics, regulatory and patients acceptance aspects of CAR-T Cell therapies

### **P63 THE HUMANIZATION OF CARE FOR PATIENTS WHO PERFORM THERAPY CART IN AN ONCO-HEMATOLOGY PEDIATRIC UNIT**

M.A. Juncà Guillaumes (Hospital Sant Joan De Déu, Barcelona, Spain)

### **P64 SETTING UP A CAR T CELL UNIT CAN BE FACILITATED FROM PREVIOUS CLINICAL EXPERIENCE IN ALLOGENEIC BMT PATIENTS OF THE TEAM?**

D. Dubali (Istituto di Ematologia "Lorenzo e Ariosto Seràgnoli", Policlinico Universitario Sant'Orsola - Malpighi, Bologna, Italy)

### **P65 LYMPHODEPLETION AND CAR-T INFUSION IN AMBULATORY CARE (AC) SETTING: A SAFE AND COST-EFFECTIVE APPROACH DELIVERING EXCELLENT PATIENT EXPERIENCE**

A.C. Colada (University College London Hospitals NHS Trust, London, United Kingdom)

### **P66 CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS IN CLINICAL TREATMENT OF CANCER PATIENTS: THE ROLE OF CAR-T SPECIALIST**

I. Defrancesco (University of Pavia, Pavia, Italy)

### **P67 STRATEGIES FOR THE IMPLEMENTATION AND DEVELOPMENT OF A CLINICAL PROGRAMME FOR CAR-T CELL THERAPY IN PATIENTS WITH REFRACTORY PRE-B ACUTE LYMPHOBLASTIC LEUKEMIA IN A DEVELOPING (O LOW/MEDIUM-INCOME) COUNTRY**

A. Olaya-Vargas (National Institute of Pediatrics, México City, Mexico)

### **P68 FAILURE MODE, EFFECTS, AND CRITICALITY ANALYSIS (FMECA) OF CAR-T CELLS PHARMACEUTICAL CIRCUIT IN A FRENCH HOSPITAL**

M. Mebarki (Saint Louis Hospital, Paris, France)

### **P69 EVALUATION OF LEUKOCYTAPHERESIS PERFORMED FOR THE PRODUCTION OF AN ACADEMIC AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS**

J. Cid (Hospital Clínic, Barcelona, Spain)

# Faculty Index

---

## **ABIA HEREU, ANNA**

Hospital Vall d'Hebron, Barcelona, Spain

Disclosures: No affiliations

## **ABRAMSON, JEREMY**

Massachusetts General Hospital, Boston, United States

Disclosures: Abbvie (Consulting); Allogene (Consulting); Celgene (Consulting, research support); EMD Serono (Consulting); Genentech/Roche (Consulting); Karyopharm (Consulting); Kite Pharma (Consulting); Morphosys (Consulting); Novartis (Consulting); Seattle Genetics (Research support)

## **AERTS, ERIK**

Haematology Nurses and Healthcare Professionals Group, Winterthur, Switzerland

Disclosures: No affiliations

## **ALEXANDER, PHILIP**

King's College Hospital, London, United Kingdom

Disclosures: No affiliations

## **AMROLIA, PERSIS**

UCL Great Ormond St Institute of Child Health, London, United Kingdom

Disclosures: Autolus (Royalties for IP); Bluebird Bio (Research funding); Allovir (Advisory board)

## **ASSENMACHER, MARIO**

Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany

Disclosures: No affiliations

## **BADER, PETER**

University Hospital Frankfurt, Frankfurt, Germany

Disclosures: Novartis (Consultancy, speaker's bureau, honoraria); Medac (Research funding, patents and royalties, honoraria); Riemser (Research funding, honoraria); Neovii (Research funding, honoraria); Jazz Pharmaceuticals (Honoraria); Amgen (Honoraria)

## **BARUCHEL, ANDRE**

Hôpital Robert Debre, Paris, France

Disclosures: Novartis (Advisory boards, satellite symposium); Servier (Advisory boards, research grant); Celgene (Advisory board); Jazz (Advisory boards, satellite symposium); Amgen (Advisory board); Janssen (Satellite symposium); Astrzeneca (Satellite symposium)

## **BENJAMIN, REUBEN**

King's College Hospital, London, United Kingdom

Disclosures: Servier (Research funding); Pfizer (Research funding); Allogene (Research funding); Celgene (Advisory board); Gilead (Advisory board); Novartis (Advisory board); Takeda (Advisory board); EUSA Pharma (Advisory board)

## **BERQUIER, MAXIME**

Hôpital Saint Louis, Paris, France

Disclosures: Kite / Gilead (Advisory board, speaker); Novartis (Advisory board, speaker)

# Faculty Index

---

## **BOLAÑOS, NATACHA**

Lymphoma Coalition, Madrid, Spain

Disclosures: No affiliations

## **BÖNIG, HALVARD**

German Red Cross Blood Donation Service, Institute Frankfurt, Frankfurt, Germany

Disclosures: Medac (Royalties, licensing fees); Therumo BCT (research support, honoraria, speakers' fee, Advisory Board); Chugai (Research support, honoraria, speakers' fee); Polyphor (Research support); Sandoz- Hexal (Research support, honoraria, speakers' fee, advisory board); Bayer (Research support); Uniqure (Research support); Erydel (Research support); Miltenyi (Research support, honoraria, speakers' fee); Stage (Research support); Celgene (Honoraria, speakers' fee, advisory board); Fresenius (Honoraria, speakers' fee); Kiadis (Honoraria, speakers' fee); Genzyme (Advisory board); Novartis (Advisory board); Stage (Advisory board); Siemens Healthineers (Advisory board); Stock (Advisory board)

## **BONINI, CHIARA**

Ospedale San Raffaele, Milan, Italy

Disclosures: Allogene (Advisory committee); GSK (Advisory committee); Intellia Therapeutics (Advisory committee, research funding); Kite/Gilead (Advisory committee); Molmed (Advisory committee); Novartis (Advisory committee); TxCELL (Advisory committee)

## **BRIONES, JAVIER**

Hospital Santa Creu i Sant Pau, Barcelona, Spain

Disclosures: Novartis (Advisory board); Celgene (Advisory board); Gilead (Research support, advisory board)

## **BÜSCH, DIRK**

Med. Mikrobiologie, Immunologie und Hygiene, Munich, Germany

Disclosures: Affiliations unknown

## **CANO RUIZ, JOSEFA MARÍA**

Vall d'Hebron Hospital, Barcelona, Spain

Disclosures: No affiliations

## **CHABANNON, CHRISTIAN**

Institut Paoli-Calmettes & Aix-Marseille Université, Marseille, France

Disclosures: Sanofi S.A. (Advisory board, speaker's bureau, grant); Kite / Gilead (Advisory board, speaker's bureau, hospitalities); Novartis (Speaker's bureau); Celgene (Advisory board); Janssen (Advisory board); Bellicum (Advisory board); Terumo BCT (Speaker's bureau); Fresenius Kabi (Research support); Miltenyi biotec (Research support)

## **CHOMIENNE, CHRISTINE**

IRSL St Louis, Paris, France

Disclosures: No affiliations

## **CICERI, FABIO**

San Raffaele Scientific Institute, Milan, Italy

Disclosures: No affiliations



# Faculty Index

---

## **CLOUT, RUTH**

The Christie NHS Foundation Trust, Manchester, United Kingdom

Disclosures: Kite (Gilead); (Speaker honorarium)

## **DUDEK, BETHANY**

Kite Pharma, a Gilead Company, Amsterdam, The Netherlands

Disclosures: Kite Pharma, a Gilead Company (Employee)

## **EHNINGER, GERHARD**

Technical University, Dresden, Germany

Disclosures: Cellex (CEO); GEMoB (CMO)

## **EINSELE, HERMANN**

University Hospital Würzburg, Würzburg, Germany

Disclosures: Amgen (Research support, consultant, scientific advisory board, honorarium); Janssen (Research support, consultant, scientific advisory board, honorarium); Celgene (Research support, consultant, scientific advisory board, honorarium); BMS (Research support, consultant, scientific advisory board, honorarium); Novartis (Research support, consultant, scientific advisory board, honorarium); Takeda (Research support, consultant, scientific advisory board, honorarium)

## **ELLARD, ROSE LOUISE**

Royal Marsden Hospital, London, United Kingdom

Disclosures: Molmed (Honoraria); Kite Gilead (Travel grant, honoraria)

## **GARCIA LOPEZ, TAMARA**

The Christie NHS Foundation Trust, Manchester, United Kingdom

Disclosures: No affiliations

## **GRIBBEN, JOHN**

Barts Cancer Institute, London, United Kingdom

Disclosures: Janssen (Grant funding, scientific advisory board, honoraria, PI of clinical trials); Acerta (Grant funding, honoraria); Celgene (Grant funding, scientific advisory board, honoraria); NIH (Grant funding); Wellcome Trust (Grant funding); Cancer Research UK (Grant funding); MRC (Grant funding); Abbvie (Scientific advisory board, honoraria); Gilead (Scientific advisory board); Pharmacyclics (Scientific advisory board, honoraria, PI of clinical trials); Roche/Genentech (Scientific advisory board, honoraria, PI of clinical trials); AZ (Honoraria); Morphosys (Honoraria); Kite/Gilead (Honoraria, PI of clinical trials); BeiGene (PI of clinical trials); Novartis (Honoraria, PI of clinical trials); Merck (PI of clinical trials); Epizyme (PI of clinical trials); Takeda (PI of clinical trials); TG Therapeutics (Honoraria, PI of clinical trials)

## **GUEDAN CARRIO, SÒNIA**

IDIBAPS, Barcelona, Spain

Disclosures: Gilead (Grant); Novartis (Patent holder)

## **HAAG, CORNELIA**

University Hospital, Dresden, Germany

Disclosures: No affiliations

# Faculty Index

---

## **HEEMSKERK, MIRJAM**

LUMC, Leiden, The Netherlands

Disclosures: No affiliations

## **HERR, WOLFGANG**

University Hospital Regensburg, Regensburg, Germany

Disclosures: No affiliations

## **HOSEN, NAOKI**

Osaka University Graduate School of Medicine, Osaka, Japan

Disclosures: Otsuka Pharmaceutical Co., Ltd. (Research funding)

## **HUDECEK, MICHAEL**

Universitätsklinikum Würzburg, Würzburg, Germany

Disclosures: Universitätsklinikum Würzburg (Speaker's bureau)

## **HUPPA, JOHANNES**

Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria

Disclosures: No affiliations

## **HUTT, DAPHNA**

Sheba Medical Center, Ramat Gan, Israel

Disclosures: No affiliations

## **IVICS, ZOLTAN**

Paul Ehrlich Institute, Langen, Germany

Disclosures: No affiliations

## **JACOBY, ELAD**

Sheba Medical Center, Tel Hashomer, Israel

Disclosures: Novartis (Honoraria); Lonza (Advisory board)

## **JACQUEMIN, VIRGINIE**

Servier, Suresnes, France

Disclosures: Servier (full-time employee)

## **JÄGER, ULRICH**

Medical University of Vienna, Vienna, Austria

Disclosures: AbbVie (Research support); Amgen (Honoraria); AOP Orphan (Honoraria); Bioverativ-Sanofi (Research support, honoraria); BMS (Honoraria); Celgene (Research support, honoraria); Gilead (Research support, honoraria, advisory board); Janssen (Research support, honoraria, advisory board); Miltenyi (Honoraria, advisory board); MSD (Research support); Mundipharma (Honoraria, advisory board); Novartis (Research support, consultant, honoraria, advisory board); Roche (Research support, consultant, honoraria, advisory board); Sandoz (Honoraria); Takeda-Millennium (Research support, honoraria, advisory board)

## **JUAN OTERO, MANUEL**

Hospital Clínic de Barcelona, Barcelona, Spain

Disclosures: No affiliations

# Faculty Index

---

## **JUNE, CARL**

University of Pennsylvania, Philadelphia, United States

Disclosures: Affiliations unknown

## **KENYON, MICHELLE**

King's College Hospital NHS Foundation Trust, London, United Kingdom

Disclosures: Jazz Pharmaceuticals (Honoraria)

## **KERSTEN, MARIE JOSE**

Amsterdam UMC, Amsterdam, The Netherlands

Disclosures: No affiliations

## **KÖHL, ULRIKE**

Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany

Disclosures: No affiliations

## **KRÖGER, NICOLAUS**

University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Disclosures: Novartis (Honoraria, research funding); Riemsler (Research funding); Celgene (Honoraria, research funding); Sanofi (Honoraria); Medac (Honoraria); Neovii (Honoraria, research funding)

## **KUBALL, JÜRGEN**

University Medical Center Utrecht, Utrecht, The Netherlands

Disclosures: Novartis (Grant); Miltenyi (Grant); Gadeta (Shareholder, scientific advisor)

## **KÜNKELE, ANNETTE**

Charité - University Medicine Berlin, Berlin, Germany

Disclosures: No affiliations

## **LATORRE, LUIS ALEJANDRO**

Spain

Disclosures: Affiliations unknown

## **LEDERGERBER, DOROTHEA**

Novartis, Stein, Switzerland

Disclosures: No affiliations

## **LEVINE, BRUCE**

University of Pennsylvania, Philadelphia, United States

Disclosures: CRC Oncology (Consultancy fee); Novartis (Consultancy fee); Terumo (Consultancy fee); Lilly Asia Ventures (Consultancy fee); Avectas (Scientific advisory board); Brammer Bio/TF Viral Vector Services (Scientific advisory board); Immuneel (Scientific advisory board); Ori Biotech (Scientific advisory board); Vycellix (Scientific advisory board); Tmunity Therapeutics (Co-founder, equity holder)

## **LOCATELLI, FRANCO**

Sapienza University of Rome, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

Disclosures: Novartis (Advisory board, speaker's bureau); Amgen (Advisory board, speaker's bureau); Bluebirdbio (Advisory board, speaker's bureau); Miltenyi (Advisory board, speaker's bureau)

# Faculty Index

---

## **MACKALL, CRYSTALL**

Stanford University, Stanford, United States

Disclosures: Affiliations unknown

## **MACKENSEN, ANDREAS**

University Hospital of Erlangen, Erlangen, Germany

Disclosures: No affiliations

## **MIELKE, STEPHAN**

Karolinska University Hospital, Stockholm, Sweden

Disclosures: Gilead (Expert panel); Novartis (Speaker fees); Celgene (Speaker fee); Miltenyi (Speaker fee, data safety monitoring board); Kiadis Pharma (Speaker fee); Bellicum (Expert panel)

## **MOHTY, MOHAMAD**

INSERM, Paris, France

Disclosures: Affiliations unknown

## **MURRAY, JOHN**

The Christie NHS FT, Manchester, United Kingdom

Disclosures: Therakos (Speaker honoraria); Jazz (Speaker honoraria); Kite/Gilead (Speaker honoraria)

## **NAGLER, ARNON**

Chaim Sheba Medical Center, Ramat Gan, Israel

Disclosures: No affiliations

## **NÍ CHONGHAILE, MAIRÉAD**

HNHCP/ St James's Hospital, Dublin, Ireland

Disclosures: Jazz Pharmaceuticals (Speaker's bureau, advisory board)

## **OSTUNI, EMANUELE**

Novartis, Switzerland

Disclosures: Novartis (Head of Europe, Cell and Gene Therapy)

## **PAMIAS NOGUÉ, MARTA**

Institut Català d'Oncologia Hospitalet, Barcelona, Spain

Disclosures: No affiliations

## **PASQUINI, MARCELO**

CIBMTR, Milwaukee, United States

Disclosures: Novartis (Research support); Kite (Research support); Celgene (Research support, consultant); Amgen (Research support, consultant); Medigene (Consultant); Pfizer (Consultant)

## **PEDRAZZOLI, PAOLO**

IRCCS Fondazione San Matteo, Pavia, Italy

Disclosures: No affiliations

# Faculty Index

---

## **PULE, MARTIN**

Autolus Ltd, London, United Kingdom

Disclosures: Affiliations unknown

## **QASIM, WASEEM**

Great Ormond Street Institute of Child Health, London, United Kingdom

Disclosures: Servier (Clinical trial funding); Cellectis (Research support); Bellicum (Clinical trial funding);

Autolus (Stock); Orchard (Stock)

## **RAUSER, GEORG**

Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany

Disclosures: Miltenyi Biotec B.V. (Employee)

## **REZVANI, KATY**

MD Anderson Cancer Center, Houston, United States

Disclosures: Affimed (Grant, research support); Pharmacyclics (Grant, research support); EMD Serono

(Paid consultant); Adicet Bio (Paid consultant); Onkimmune (Paid consultant); Formula Pharma

(Paid consultant); Virogen (Paid consultant); SAB (Advisory board); Formula Pharma (Advisory board);

Virogen (Advisory board); Kiadis Pharma (Advisory board)

## **RIDDELL, STANLEY**

Fred Hutchinson Cancer Research Center, Seattle, United States

Disclosures: Lyell Immunopharma (Co-founder, employee)

## **RODDIE, CLAIRE**

University College London (UCL), London, United Kingdom

Disclosures: Novartis (Speaker fees; advisory board); Kite/Gilead (Speaker fees);

Celgene (Speaker fees, advisory board)

## **RÖSSIG, CLAUDIA**

University Children's Hospital Münster, Münster, Germany

Disclosures: Amgen (Advisory board, speaker honoraria); BMS (Speaker honoraria); Celgene (Advisory board);

EUSA Pharma (Advisory board); Genentech (Advisory board); Novartis (Advisory board);

Pfizer (Speaker honoraria); Roche (Advisory board, speaker honoraria)

## **SADELAIN, MICHAEL**

Memorial Sloan Kettering Cancer Center, New York City, United States

Disclosures: Atara (Research support); Takeda Pharmaceuticals (Research support);

Fate Therapeutics (Research support)

## **SALLES, GILLES**

University of Lyon, Pierre Benite, France

Disclosures: Abbvie (Advisory board / consultancy honoraria, lecture honoraria); Autolus (Advisory board /

consultancy honoraria); Celgene (Advisory board / consultancy honoraria, lecture honoraria); Gilead (Advisory

board / consultancy honoraria, lecture honoraria); Epizyme (Advisory board / consultancy honoraria);

Janssen (Advisory board / consultancy honoraria, lecture honoraria); Karyopharm (Advisory board / consultancy

honoraria); Kite (Advisory board / consultancy honoraria, lecture honoraria); Merck (Advisory board /

consultancy honoraria); Morphosys (Advisory board / consultancy honoraria, lecture honoraria); Novartis

(Advisory board / consultancy honoraria, lecture honoraria); Roche (Advisory board / consultancy honoraria,

lecture honoraria); Servier (Advisory board / consultancy honoraria, lecture honoraria); Takeda (Advisory board /

consultancy honoraria, lecture honoraria); Amgen (Lecture honoraria)

# Faculty Index

---

## **SCHÜSSLER-LENZ, MARTINA**

Paul-Ehrlich-Institut, German Agency for Vaccines and Biomedicines, Langen, Germany

Disclosures: No affiliations

## **SINDERN, JÖRN**

Janssen, Belgium

Disclosures: Janssen (Director HEMAR)

## **SPECHT, JENNIFER**

Fred Hutchinson Cancer Research Center, Seattle, United States

Disclosures: Genentech (Institutional research funding); Seattle Genetics (Institutional research funding);

Myriad Pharmaceuticals (Institutional research funding); Novartis (Institutional research funding);

Cascadian Therapeutics (Institutional research funding); Nektar Therapeutics (Institutional research funding);

Merck (Institutional research funding); Pfizer (Institutional research funding); Minerva Biotechnologies

Corporation (Institutional research funding); Nektar Therapeutics (Advisory board, travel support, honoraria);

Genomic Health (Advisory board honoraria); Daiichi Sankyo (Advisory board honoraria)

## **STOLARCZYK, LUCASZ**

EBMT Registry, London, United Kingdom

Disclosures: No affiliations

## **THEMELI, MARIA**

Amsterdam University Medical Centers, Amsterdam, The Netherlands

Disclosures: Covagen AG (Advisory board)

## **THIEBLEMONT, CATHERINE**

Saint Louis Hospital, AP-HP, Paris, France

Disclosures: No affiliations

## **URBANO-ISPIZUA, ALVARO**

Hospital Clinic of Barcelona, Barcelona, Spain

Disclosures: No affiliations

## **UYL-DE GROOT, CARIN**

Erasmus School of Health Policy and Management, Rotterdam, The Netherlands

Disclosures: Affiliations unknown

## **VAN BIEZEN, ANJA**

EBMT Office, Leiden, The Netherlands

Disclosures: No affiliations

## **VAN DEN BRINK, MARCEL**

Memorial Sloan Kettering Cancer Center, New York City, United States

Disclosures: Seres Therapeutics (Research support, consultation fees, honoraria, advisory board, IP Licensing);

Flagship Ventures (Consultation fees, honoraria, advisory board); Novartis (Consultation fees, honoraria, advisory

board); Evelo (Consultation fees, honoraria, advisory board); Jazz Pharmaceuticals (Consultation fees, honoraria,

advisory board); Therakos (Consultation fees, honoraria, advisory board); Amgen (Consultation fees, honoraria,

advisory board); Magenta Therapeutics (Consultation fees, honoraria, advisory board); WindMIL Therapeutics

(Consultation fees, honoraria, advisory board); Merck & Co, Inc (Consultation fees, honoraria, advisory board);

Acute Leukemia Forum (ALF) (Consultation fees, honoraria, advisory board); DKMS Medical Council (Consultation

fees, honoraria, advisory board); Juno Therapeutics (IP Licensing); Smart Immune (stock options)

# Faculty Index

---

**VERHOEVEN, BREGJE**

Foundation Hematon, Utrecht, The Netherlands

Disclosures: Amgen (Consultancy); Janssen (Speaker, patient advisory group); Takeda (Consultancy)

**VICKERS, ELAINE**

Science Communicated Ltd., Manchester, United Kingdom

Disclosures: No affiliations

**WANG, JIANXANG**

Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China

Disclosures: Celgene (Grant)

**WELS, WINFRIED**

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany

Disclosures: No affiliations

**YAKOUB-AGHA, IBRAHIM**

Hopital Huriez, Lille, France

Disclosures: Gilead (Honorarium); Novartis (Honorarium); Celgene (Honorarium); Astellas (Honorarium)